We wrote about CRISPR Therapeutics (CRSP) on January 6 and said traders should "Continue to hold longs risking to $149 now. Our price targets are $200 and $230 for now." CRSP is now trading around $215 so I think another look at the stock is warranted and perhaps a change in strategy.
More from Investing
Companies don't become best of breed unless they are the best in everything they do. Facebook hangs in the balance.
Traders continue to hunt for good action as the gap narrows between extended big-cap stocks and beat-down smaller names.
The announcement is welcome because it ensures production predictability, though deliveries scheduled for next year have come down a bit.
The big question is what Evergrande's troubles mean for China's real estate market more broadly, and the answer may be an unpleasant one.
The construction company's shares are trading below net current asset value, which is a rarity among value stocks in the current market.